Previous close | 1.1600 |
Open | 1.1600 |
Bid | 0.6500 |
Ask | 1.1000 |
Strike | 2.50 |
Expiry date | 2024-07-19 |
Day's range | 1.1600 - 1.1600 |
Contract range | N/A |
Volume | |
Open interest | 102 |
Lyell Immunopharma Inc (NASDAQ:LYEL) shares are trading lower on Wednesday on a heavy session volume of 5.79 million shares as per data from Benzinga Pro. The company released initial clinical and translational data from its Phase 1 trial of LYL797, its first-generation reprogrammed ROR1 CAR T‑cell product candidate enhanced with proprietary anti-exhaustion technology. This initial dataset of 20 treated patients includes 16 patients with TNBC and four patients with non-small cell lung cancer and
Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date (150 x 106 CAR T cells)First demonstration that CAR T cells enhanced with anti-exhaustion technology can both expand and infiltrate into solid tumorsNo significant safety signal related to LYL797 observed in patients without lung involvement; treatable pneumonitis observed in patients with lung metasta
SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10 at 4:00 pm ET. A live webcast of the presentation can be accessed through the Investors section of the Company's w